Restalyst will be participating in Medica 2024 this coming November 2024. . Restalyst will be participating in Medica, one of the largest medical trade fair in the world for medical technology and healthcare, from 11…

Restalyst received regulatory approval from DMEHW in Vietnam. . Restalyst 3 cancer diagnostic solutions namely, NPC-REAAD™ EBV EA-IgA ELISA, GC-REAAD™ ITIH3 ELISA, and HCC-REAAD™ ERBB3 ELISA have been approved for clinical use in Vietnam.

Restalyst launched new diagnostic assays for Nasopharyngeal Carcinoma and granted Special Access Route (SAR) from Health Sciences Authority, Singapore. . The early detection of Nasopharyngeal carcinoma via diagnostic screening in the laboratory is essential in…

This project is aimed to study the diagnostic performance of ERBB3 using Restalyst‘s HCC-REAAD™ ERBB3 ELISA together with its diagnostic algorithm for early detection of Hepatocellular Carcinoma in Southern Asia population.

COVID19N-REAAD™ is intended for professional use in detecting COVID-19 patients by detecting patient’s anti-SARS-CoV-2 antibodies. IgG antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although the duration of antibodies is…

This is a product intended for qualitative & quantitative detection of IgG antibodies to SARS-CoV-2 proteins in human serum and plasma.

Project to investigate the use of ITIH3 biomarker in screening of individuals with gastric cancer risk

Singapore biomedical firm Restalyst has developed a COVID-19 antibody test, COVID19N-REAAD™, which will be instrumental in establishing disease prevalence in populations and the exposure risk factors associated with infection. Press release was made to countries…

This is a product intended for qualitative detection of IgG antibodies to SARS-CoV-2 Nucleocapsid Protein in human serum and plasma.

This a lateral flow chromatography immunoassay intended for the qualitative detection and differentiation of IgM and IgG antibodies against SARS-CoV-2 in human plasma, serum, finger pricked whole blood or whole blood.

18-21 Nov 2019. Restalyst participated in Medica 2019 under the Singapore Pavilion to promote her innovative cancer tests to the world.

12 – 15 Nov 2018 As part of its commitment to continuous innovation, Restalyst will be participating in Medica 2018. Visit us at Singapore Pavilion Hall 3 Booth G74.

GC-REAAD™, an in-vitro diagnostic medical device for the early detection of gastric cancer, was developed based on competitive ELISA platform in 2015. It was recently improved to a sandwich ELISA platform and approved by Singapore…

Restalyst press release 2017

This ELISA-based diagnostic kit (known as HCC REAAD) was developed by Restalyst based on patented technology by the Chang Gung Memorial Hospital (Taiwan).

This ELISA-based diagnostic kit (known as GC-REAAD) was developed by Restalyst together with the National University of Singapore.